NM_000329.3(RPE65):c.1101A>G (p.Arg367=) is a synonymous variant located in the third nucleotide of exon 10. This variant is absent from gnomAD v2.1.1 (PM2_Supporting). The splicing impact predictor SpliceAI gives a score of 0.99 for donor gain, which is above the ClinGen LCA / eoRD VCEP recommended threshold of ≥0.2 and predicts a damaging impact on splicing. This prediction has been confirmed by a minigene assay showing complete disruption of splicing and production of an alternative transcript with an out-of-frame truncation of 28 base pairs, which is supportive of a damaging effect on protein function (PMID: 28714225). These in silico and experimental findings have not been used to meet the PP3 and PS3_Supporting codes, but rather combined to meet the PVS1(RNA) code. At least one proband harboring this variant exhibits a phenotype including clinical diagnosis of Leber congenital amaurosis (0.5 pts), previous 100+ retinal dystrophy gene panel testing that did not provide an alternative explanation for visual impairment (2 pts), decreased central visual acuity (1 pt), onset between birth and 5 years old (1 pt), pigmentary retinopathy with attenuated vessels (0.5 pts), RPE mottling (0.5 pts) and macular atrophy (0.5 pts), which together are specific for RPE65-related recessive retinopathy (6 pts, PMID: 28714225, PMID: 32865313, PP4). This variant has been reported in at least 2 probands with early-onset severe retinal dystrophy who were compound heterozygous with either the NM_000329.3(RPE65):c.1022T>C (p.Leu341Ser) or NM_000329.3(RPE65):c.272G>A (p.Arg91Gln) variants suspected in trans (1 point, PMID: 36909829, 28714225), which were previously classified as pathogenic by the ClinGen LCA / eoRD VCEP (PM3). In summary, this variant meets the criteria to be classified as pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PVS1, PM2_Supporting, PM3, PP4. (VCEP specifications version 1.0.0; date of approval 09/21/2023).